

## Review

# Diagnosis and treatment of severe sepsis

Yann-Erick Claessens<sup>1-3</sup> and Jean-François Dhainaut<sup>1-3</sup>

<sup>1</sup>Pôle Réanimations-Urgences, Hôpital Cochin, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, Paris, France

<sup>2</sup>Paris Descartes University, rue de l'école de Médecine, 75270 Paris Cedex 06, Paris, France

<sup>3</sup>Y-EC and J-FD contributed equally to this work.

Corresponding author: Jean-François Dhainaut, [president@univ-paris5.fr](mailto:president@univ-paris5.fr)

Published: 19 December 2007

This article is online at <http://ccforum.com/content/11/S5/S2>

© 2007 BioMed Central Ltd

*Critical Care* 2007, **11(Suppl 5):S2** (doi:10.1186/cc6153)

## Abstract

The burden of infection in industrialized countries has prompted considerable effort to improve the outcomes of patients with sepsis. This has been formalized through the Surviving Sepsis Campaign 'bundles', derived from the recommendations of 11 professional societies, which have promoted global improvement in those practices whose primary goal it is to reduce sepsis-related death. However, difficulties remain in implementing all of the procedures recommended by the experts, despite the apparent pragmatism of those procedures. We summarize the main proposals made by the Surviving Sepsis Campaign and focus on the difficulties associated with making a proper diagnosis and supplying adequate treatment promptly to septic patients.

## Introduction

Severe sepsis and septic shock are currently among the most common causes of morbidity and mortality in intensive care, and their incidences have increased during the past decade as the population has aged [1,2]. The emergency department (ED), where patients are treated for community-acquired infection, many of whom require intensive care unit (ICU) management [3], has been identified as a setting in which these syndromes and their outcomes may readily be observed.

Despite dramatic improvements in diagnostic and treatment procedures, mortality rates among patients with sepsis remained unchanged from the 1960s through to the late 1990s. Diagnostic algorithms have therefore been developed to identify at-risk populations, and professional societies have worked to implement treatment procedures that focus efforts on early intervention. The Surviving Sepsis Campaign proposed management procedures that differentiate between 'resuscitation bundles' for the first 6 hours and 'management bundles' to be applied until the end of the 24th hour [4]. These procedure recommendations have been disseminated

worldwide and are focused on global improvement in practices whose primary goal it is to reduce sepsis-related death. As a consequence of the recommendations, a trend toward decreasing mortality has been observed during the past few years.

Difficulties remain, however, in applying all of the procedures recommended by the experts. This article summarizes the main proposals raised by the Surviving Sepsis Campaign and focuses on the difficulties associated with applying these guidelines in an appropriate time frame.

## Diagnosis of sepsis and severity assessment

Definitions of sepsis, severe sepsis, and septic shock were proposed 15 years ago. They were based on expert advice and used criteria that identify progression of the infection along with appropriate responses [5]. However, these criteria are clearly inadequate in terms of allowing detection of severe infections in routine daily practice. A study of a large multicenter cohort of ICU patients with infection [6] concluded that simply categorizing an infectious process as 'sepsis' or 'severe sepsis' did not predict prognosis. A high score indicating a septic condition did not necessarily predict a patient's outcome, even though that outcome might be affected by sepsis-related organ dysfunction.

With regard to patients presenting at the ED because of community-acquired pneumonia (CAP), a recent report from Dremiszov and coworkers [7] illustrated the limited value of the well established criteria for 'systemic inflammatory response syndrome' (SIRS) in predicting outcome. That work emphasizes the inability of the SIRS designation to identify which infected patients were at risk for developing severe sepsis or shock. These findings prompted experts to propose new scoring systems aimed at identifying patients who are at

CAP = community-acquired pneumonia; ED = emergency department; EGDT = early goal-directed therapy; ICU = intensive care unit; MEDS = Mortality in Emergency Department Sepsis; rhAPC = recombinant human activated protein C; ScvO<sub>2</sub> = central venous oxygen saturation; SIRS = systemic inflammatory response syndrome.

risk for developing severe conditions related to infection. Shapiro and coworkers developed the Mortality in Emergency Department Sepsis (MEDS) score to predict 28-day [8] and 1-year [9] outcomes in patients presenting at an ED with infection, and calculation of this score requires data that are immediately available in the ED. Despite its ability to predict all-cause death in the study population, the accuracy of the MEDS score has not been tested at the individual patient level; its use at the bedside has not been evaluated, and therefore this tool should not be used in decisions regarding triage and ICU referral [10]. Most of the other newly developed scoring systems appear to have only marginal utility in daily routine practice because they require microbiologic identification and 24-hour clinical evaluation; hence, they lack the immediacy that is required for decision making in emergency medicine [6]. To date, the Pneumonia Severity Index is the only scoring system that is considered to help physicians to assess severity of illness in the ED [11]. Using this score at the bedside allows better triage of low-risk patients [12-14], but it does not alter outcomes in more severe pneumonia [15], in which it is only slightly more effective than the inadequate SIRS classification [7].

Evaluation of biologic factors also may help in determining the severity of illness. Cady and coworkers [16] proposed use of the arterial blood lactate level to identify patients with severe illness and to assess the severity of sepsis. The Surviving Sepsis Campaign Management Guidelines Committee [4], and the American College of Chest Physicians and the Society of Critical Care Medicine Consensus Conference Committee [17] have also proposed guidelines that help to identify those patients who are at greater risk for sepsis. Recent reports from Shapiro [18] and Nguyen [19] and their colleagues have emphasized the importance of lactate clearance in identifying those patients who will respond to treatment and have a favorable outcome. Lactate clearance was shown to be a better prognostic factor than a single lactate determination performed on ED admission [18,19]. However, a single venous lactate measurement above 4 mmol/l predicted short-term and in-hospital risk for death in patients presenting at the ED with suspected infection [20], even in those with normal arterial blood pressure [21]. A single lactate dosage is thus a valuable tool that may facilitate early detection of at-risk patients. Plasma procalcitonin may also be valuable in this setting. Procalcitonin is a more specific test than C-reactive protein [22] and interleukin-6, and can help the physician to detect sepsis [23]. Higher levels of procalcitonin are sufficiently specific to identify those septic patients who will develop severe sepsis, but it is not sensitive enough for routine use in ED triage [24].

### Antibiotics: fast and fitted

It is clear that the site of infection should be managed promptly in patients with severe infection, including emergency surgery when applicable. However, efforts should also focus on early and carefully controlled antimicrobial therapy.

Minimizing the delay between admission and beginning antimicrobial treatment is key to achieving a successful outcome.

The potential influence of delayed antibiotic therapy was first evaluated in patients with CAP. In a series of 18,209 Medicare patients older than 65 years admitted because of CAP [25], the antibiotic regimen used saved lives when the first dose was administered before hour 4 after admission. Of note, fewer than 50% of patients received antibiotics during the first 4 hours in this study and as many as 17% received antimicrobial treatment after hour 6. Those patients in whom administration of antimicrobial agents was delayed were elderly people with an atypical CAP presentation, or they exhibited clinical features inconsistent with a diagnosis of sepsis, such as the absence of fever and altered mental status [26] (specifically, patients in whom the diagnosis of infection was not obvious). Such a lack of aggressive and early antimicrobial therapy has been identified in various settings in which patients were being treated for such conditions as meningitis, cancer, CAP, and nosocomial pneumonia [27-33]. A recent retrospective analysis quantified the impact of delayed antimicrobial treatment in patients with severe sepsis. Kumar and coworkers [34] demonstrated that every additional hour without antibiotics increased the risk for death in hypotensive septic patients by 7.6% during the first 6 hours. Early antibiotic therapy has been incorporated into the Surviving Sepsis Campaign recommendations [35], and we expect compliance with this component of the guidelines to increase from its current low level [36].

The focus of infection is sometimes difficult to ascertain, but treatment must effectively target the responsible pathogen, from among a wide range of potentially etiologic agents [37]. Initial selection of an antimicrobial agent with good activity against the causative organism is crucial for survival. A prospective evaluation of sepsis [38] emphasized that, other than comorbidity, the factor most strongly associated with death was ineffectiveness of antimicrobial treatment against the micro-organism identified in blood cultures. Several large reports corroborated the relation between ineffective antibiotic treatment and poor prognosis. Consequently, broad-spectrum antibiotics have been recommended, and the agent selected should provide coverage against the micro-organisms that are usually involved in the suspected focus of infection [35]. Supportive clinical evidence for use of broad-spectrum antibiotics will probably remain sparse [36], but effective antimicrobial management requires good microbiologic sense.

Adherence to such guidelines regarding use of antibiotics may positively influence prognosis [39], but efforts to improve detection of pathogens should continue because enhanced specificity allows one to focus treatment on the responsible micro-organism and so limit the spectrum of coverage. The usual microbiologic techniques of detection may lack effectiveness. The use of urine antigens to *Streptococcus*

*pneumoniae* and *Legionella pneumophila* type 1 can help in patients with pneumonia. Apart from their good sensitivity, the presence of these antigens can be detected long after an infection and, in the case of pneumococcal related infection, may reflect carriage of the micro-organism in the upper respiratory tract [40]. Sensitive genomics tools are now available to detect both bacteria and viruses, and multiplex platforms allow screening of a wide range of micro-organisms [41]. The position of these techniques in the diagnostic armamentarium is yet to be defined, but efforts to improve antimicrobial therapy must continue so that our practices and therefore outcomes may be improved in the future.

### Fluid loading

Among the symptomatic treatments, need for hemodynamic management is the most apparent, but modalities continue to be discussed and the scientific literature abounds with studies in this area. Efficient restoration of circulating blood volume is the primary goal of resuscitation in septic patients [42]. Albumin was the first product to be broadly used for intravenous fluid loading, but a meta-analysis comparing albumin with other fluid loading agents [43] identified an increased risk for death among patients who received albumin for supportive treatment during shock. However, subgroup analysis (septic patients with hypoalbuminemia) [44] revealed a trend toward greater efficiency of fluid loading with albumin. The cost-benefit balance is another factor that has restricted use of albumin, but in their recent report Guidet and colleagues [45] indicated that albumin infusion was potentially cost-effective in patients with sepsis. Thus, use of albumin should be considered with caution; it currently lacks the support needed for it to be recommended for use in patients with septic shock.

Transfusion of packed red cells may also be considered in septic patients because transfused hemoglobin may contribute to improved oxygen transport and delivery. Few controlled studies have tested this option, however, and it has been reported that liberal transfusion is potentially ineffective [46,47]. Since the publication of the findings of Rivers and coworkers [48], use of packed red cells has been regarded as a valuable approach to improving tissue oxygenation, but the specific indications for transfusion of packed red cells in this setting remain unclear.

Although controversy persists in this area, preferential use of crystalloids rather than colloids is supported by the available literature. For the same amount of volume expansion, there is no difference between these two treatments in terms of ejection stroke volume or oxygen delivery [49]. Systematic reviews and meta-analyses that included patients with sepsis and other types of patients concluded that crystalloids and colloids were generally similar in effect; an exception was one study that identified an advantage for crystalloids [50]. This finding received support from a randomized trial [51] that found that patients with septic shock receiving colloids had

greater renal impairment. A recent study [52] was conducted to compare colloid with crystalloid volume resuscitation, with the aim being to identify the safest choice for use in patients with sepsis. This study, which employed a prospective randomized multicenter design, compared the influence on outcome of Ringer's lactate versus hydroxyethyl starch and of intensive versus conventional insulin therapy in patients with severe sepsis and septic shock. Experts have already criticized this study on the grounds that its design confounds applicability of the findings to routine daily care [53]. To summarize, although infusing fluids is a cornerstone of supportive care during sepsis, the optimal modalities and volume are difficult to determine and choices should be driven by objectives in the individual patient [48].

### Vasoactive drugs

A solid rationale explains the utilization of vasopressors in daily practice [54], but the few comparative studies and the combination of different molecules account for their practical selection. Combining norepinephrine (noradrenaline) and dobutamine improved hemodynamic parameters of hepatosplanchnic circulation [55] but required invasive monitoring procedures, without clinical benefit. Dopamine and epinephrine are vasoconstrictors that also increase cardiac output, but their metabolic effects may be harmful [56,57]. In addition, use of vasopressors has been associated with poorer outcomes in septic patients, but their influence on mortality was unclear [58].

To assist physicians in their use of vasoactive drugs, professional associations have proposed guidelines that allow an opportunity to administer epinephrine or a combination of norepinephrine and dobutamine to more severely ill patients [4]. A recently reported study [59] indicated that these two strategies were equivalent in terms of both efficacy and safety. Interest in vasopressin is reflected in a growing number of publications, but the available evidence does not allow its integration into a global therapeutic scheme. However, recent data [60] may justify reconsideration of vasopressin in severe sepsis management guidelines in the near future. The VASopressin in Septic Shock Trial (VASST) study [61] is currently comparing vasopressin with norepinephrine as initial vasopressor in septic shock patients. Because the study is not yet completed, no analysis or definite conclusions can yet be drawn from this trial.

Whichever drug is selected, introduction of vasopressors should be considered after optimal fluid loading; these agents may allow therapies to be applied earlier and more aggressively in order to improve physiological parameters and ultimately outcomes [48,62].

### Applying early goal-directed therapy

In the initial management of patients with sepsis, improving physiological parameters such as blood pressure and tissue

oxygen delivery is a clear goal, as has been emphasized by experts since the late 1990s [63]. Previous studies underscored that applying an early goal-directed therapy (EGDT) approach could improve survival. The landmark study conducted by Rivers and coworkers [48] emphasized this concept in the field of sepsis. Its publication in 2001 prompted a debate in basic medical practice centered on the question, is it possible to improve outcomes in septic patients by increasing tissue oxygenation parameters during the first 6 hours of management?

The protocol proposed by Rivers and coworkers involves attainment of physiological levels of hemodynamic parameters (arterial blood pressure and central venous oxygen saturation [ $ScvO_2$ ]), by using fluid loading, vasopressors, packed red cells, and early initiation of mechanical ventilation) as rapidly as possible. The overwhelmingly positive results of this EGDT study prompted a number of ED and ICU teams to change their daily care in accordance with the study protocol. Some papers [62,64-66] reported partial or absolute adherence to the procedures evaluated by Rivers and coworkers. Others proposed adapting the procedure to their medical system with either less aggressive therapy or by forming 'sepsis teams' specifically tasked with managing patients with severe infection [67-72]. The overall result of these reports was a trend toward improved outcomes in septic patients [73].

However, these findings have been tempered by a number of barriers. Not all EDs have access to the same equipment, and ability to monitor hemodynamic parameters invasively varies widely [74]. Another unresolved issue is that not all ED physicians have the necessary resuscitation skills to administer optimal treatment, as observed in ICUs [75]. Additionally, a number of recent reports have identified the fact that EDs are increasingly overburdened. This can compromise the quality of care delivered to patients, especially those who require highly technical care that many ED physicians do not have time to practice because of ever-increasing numbers of patients [76-78].

Finally, studies are now emerging that indicate how few of the recommendations have been implemented. Early administration of antimicrobial therapy was poorly adhered to, even in recent reports. In these, although the Surviving Sepsis Campaign proposals were implemented, the mean delay to first infusion of antibiotics remained in excess of 3 hours [62], and as many as 68% of patients did not receive their first dose within this period [79]. Only a few EGDT validation studies have been conducted in EDs applying aggressive treatment outside the ICU. However, even in those EDs, mortality sometimes remained at 31% before and after the institution of procedures to improve coordination between ED and ICU [80]. In addition, effort should be maintained after the initiation of an EGDT strategy because performance dramatically decreased after initial implementation [81,82].


In addition to the pragmatism of this therapeutic approach, the optimal tools with which to evaluate attainment of physiological goals have also been subject to debate. Although  $ScvO_2$  is a valuable parameter when it is abnormal, it may be in the normal range even in severely septic patients [73]. The hemodynamic presentation, of which there are many, depends on comorbidities and stage of sepsis [83]. In addition to  $ScvO_2$ , central venous pressure may also provide useful information. A low central venous pressure indicates hypovolemia, and a high central nervous pressure with a low  $ScvO_2$  indicates myocardial suppression or mismatch of supply and demand. In any clinical situation, the findings must be interpreted alongside other clinical data. Other indicators may help, and systolic volume and pulse pressure variation of 10% or above also provide valuable information regarding blood volume [84]. Relatively liberal use of packed red cells to improve  $ScvO_2$  may be offset by its potential harm [46,47] but in the setting of severe sepsis and septic shock the theoretical risks appear balanced by the benefits in terms of tissue oxygenation [85]. Although use of central venous pressure and  $ScvO_2$  to evaluate attainment of physiologic goals can be debated [73], it is clear that defining reasonable goals to treat sepsis is important whatever the local organization and the available means to achieve those objectives are [86].

### Adjunctive therapies

For the past two decades therapeutic trials attempting to elicit a change in the host response to infection have failed to improve patients' conditions despite positive preclinical data [87-91]. However, the results of two recent studies have led to a more promising approach to this problem with recombinant human activated protein C (rhAPC) and low-dose steroids. The hemodynamic effects of steroids have been widely discussed since their use was found to allow early withdrawal of vasopressor treatment in a prospective double-blinded, multicenter study [92]. The positive effects of steroids on adrenergic receptor cycling and sodium and water balance have been proposed as explanations for this efficacy. Their anti-inflammatory role as well as their anticoagulant effect, caused by limiting membrane expression of tissue factor, may contribute to the clinical benefit. A major difficulty lies in defining adrenal deficiency in septic shock patients, and a number of definitions have thus far been used. A recent retrospective multicenter cohort study conducted by the Corticus study group [93] emphasized the importance of cortisol variation after corticotropin stimulation. That study additionally raised the possibility of a deleterious effect of etomidate on hormonal response and outcome, a concern that was previously reported by others [94]. This specific point is still subject to debate [95]. Efforts are currently being made to define the best strategy for use of steroids during sepsis.

The efficacy of rhAPC has been tested in a large multicenter study, the results of which have been widely debated. This

Figure 1



Management of severe sepsis in adults in the absence of an immediate life-threatening condition. ABP, arterial blood pressure; ACTH, adrenocorticotropic hormone; Hb, hemoglobin; RBC, red blood cell; ScvO<sub>2</sub>, central venous oxygen saturation; SpO<sub>2</sub>, pulse oximetry. Reproduced with permission from Marquis S, Roupie E: Prise en charge précoce du choc septique aux urgences/Early management of septic shock in emergency department. *Réanimation* 2006, 15:507-513.

compound was initially designed to compensate for a deficit in the natural anticoagulant protein C during sepsis, and thus it limited organ failures and improved the survival of septic shock patients [96]. Since then a number of studies have demonstrated that it has additional beneficial effects on complex interactions with inflammation, innate immunity, and apoptosis [97,98]. rhAPC also protected animals and healthy volunteers from hypotension after lipopolysaccharide challenge. A similar finding was also reported in the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) study, with more rapid improvement in hypotension and vasopressor withdrawal [99]. These clinical effects could be related to endocrine modulation (adrenomedullin was implicated in this regard) and vasoactive capacity. Mechanisms, efficacy, and safety of rhAPC are discussed in other reviews included in this supplement.

Despite the strong evidence base, use of adjunctive therapies has remained sparse in the setting of sepsis. Questionnaire surveys have attested to the under-use of such adjunctive therapies. Once again, the need for medical adherence to new therapies must be promoted by implementation of local guidelines that are inspired by the recommendations of the Surviving Sepsis Campaign (Figure 1).

### Improving standards of care

New standards of care, such as low tidal volume mechanical ventilation and tight blood glucose control, have recently

emerged and are now a cornerstone of treatment for critically ill patients. Low tidal volume ( $\leq 6$  ml/kg) as compared with 'standard' mechanical ventilation (12 ml/kg) has improved survival in patients with acute respiratory distress syndrome in independent studies [100,101]. Two landmark studies by van den Berghe and colleagues [102,103] suggested that aggressive insulin therapy improved 30-day survival in critically ill surgical patients, and reduced morbidity indicators such as weaning from mechanical ventilation and hospital days in medical ICU patients. Whereas occurrence and management of hypoglycemia appeared irrelevant in the main papers and additional data, hypoglycemia has been identified as potentially causing harm by others [104]. Even if these standards are still discussed and do not specifically impact on sepsis, they may also contribute to quality-of-care improvement and finally to patients' successful outcome [83,84].

### Conclusion

Guidelines that were proposed through the Surviving Sepsis Campaign to improve outcome in septic patients are difficult to apply routinely in most EDs. Attempts to apply these procedures fully have varied widely; diagnosis may be problematic because of atypical or unspecific presentations, biomarkers are of little help at the start of treatment and are unspecific, supportive treatment often depends on local supply of resources, and specific devices are often absent in EDs for initial therapy and monitoring. Even adherence to early administration of antibiotic therapy is poor, with delays



being common. Our goal is now to improve the level of care by applying evidence-based procedures.

### Competing interests

J-FD was an investigator in the PROWESS study and is a consultant for Eli Lilly and Company. Y-EC declares that he has no competing interests.

### Acknowledgements

We acknowledge Professor Alain Cariou for careful reading of the manuscript.

This article is part of *Critical Care* Volume 11 Supplement 5: Severe sepsis and drotrecogin alfa (activated). The full contents of the supplement are available online at <http://ccforum.com/supplements/11/S5>. Publication of the supplement has been sponsored by Eli Lilly and Company.

### References

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: **Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.** *Crit Care Med* 2001, **29**:1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M: **The epidemiology of sepsis in the United States from 1979 through 2000.** *N Engl J Med* 2003, **348**:1546-1554.
3. Strehlow MC, Emond SD, Shapiro NI, Pelletier AJ, Camargo CA Jr: **National study of emergency department visits for sepsis, 1992 to 2001.** *Ann Emerg Med* 2006, **48**:326-331.
4. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.; Surviving Sepsis Campaign Management Guidelines Committee: **Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.** *Crit Care Med* 2004, **32**:858-873.
5. Bone RC: **Sepsis, the sepsis syndrome, multiorgan failure: a plea for comparable definitions.** *Ann Intern Med* 1991, **114**:332-333.
6. Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia AR, Palazzo M, Werdan K, et al.; European Sepsis Study Group: **Systemic inflammatory response and progression to severe sepsis in critically ill infected patients.** *Am J Respir Crit Care Med* 2005, **171**:461-468.
7. Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC: **Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?** *Chest* 2006, **129**:968-978.
8. Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E, Bates DW: **Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule.** *Crit Care Med* 2003, **31**:670-675.
9. Shapiro NI, Howell MD, Talmor D, Donnino M, Ngo L, Bates DW: **Mortality in Emergency Department Sepsis (MEDS) score predicts 1-year mortality.** *Crit Care Med* 2007, **35**:192-198.
10. Carlet J: **Early goal-directed therapy of septic shock in the emergency room: who could honestly remain skeptical?** *Crit Care Med* 2006, **34**:2842-2843.
11. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: **A prediction rule to identify low-risk patients with community-acquired pneumonia.** *N Engl J Med* 1997, **336**:243-250.
12. Renaud B, Coma E, Labarere J, Hayon J, Roy PM, Boureaux H, Moritz F, Cibien JF, Guerin T, Carre E, et al.; Pneumocom Study Investigators: **Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study.** *Clin Infect Dis* 2007, **44**:41-49.
13. Carratala J, Fernandez-Sabe N, Ortega L, Castellsague X, Roson B, Dorca J, Fernandez-Aguera A, Verdaguer R, Martinez J, Manresa F, et al.: **Outpatient care compared with hospitaliza-**

- tion for community-acquired pneumonia: a randomized trial in low-risk patients.** *Ann Intern Med* 2005, **142**:165-172.
14. Aujesky D, Stone RA, Obrosky DS, Yealy DM, Auble TE, Meehan TP, Graff LG, Fine JM, Fine MJ: **Using randomized controlled trial data, the agreement between retrospectively and prospectively collected data comprising the pneumonia severity index was substantial.** *J Clin Epidemiol* 2005, **58**:357-363.
15. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, Graff LG, Fine JM, Fine MJ: **Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia.** *Am J Med* 2005, **118**:384-392.
16. Cady LD Jr, Weil MH, Afifi AA, Michaels SF, Liu VY, Shubin H: **Quantitation of severity of critical illness with special reference to blood lactate.** *Crit Care Med* 1973, **1**:75-80.
17. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: **Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.** *Chest* 1992, **101**:1644-1655.
18. Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, Weiss JW: **Serum lactate as a predictor of mortality in emergency department patients with infection.** *Ann Emerg Med* 2005, **45**:524-528.
19. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, Tomlanovich MC: **Early lactate clearance is associated with improved outcome in severe sepsis and septic shock.** *Crit Care Med* 2004, **32**:1637-1642.
20. Trzeciak S, Dellinger RP, Chansky ME, Arnold RC, Schorr C, Milcarek B, Hollenberg SM, Parrillo JE: **Serum lactate as a predictor of mortality in patients with infection.** *Intensive Care Med* 2007, **33**:970-977.
21. Howell MD, Donnino M, Clardy P, Talmor D, Shapiro NI: **Occult hypoperfusion and mortality in patients with suspected infection.** *Intensive Care Med* 2007, **33**:1892-1899.
22. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J: **Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.** *Clin Infect Dis* 2004, **39**:206-217.
23. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J, Geneva Sepsis Network: **Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.** *Am J Respir Crit Care Med* 2001, **164**:396-402.
24. Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B: **Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study.** *Clin Infect Dis* 2002, **34**:895-901.
25. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG: **Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.** *Arch Intern Med* 2004, **164**:637-644.
26. Metersky ML, Sweeney TA, Getzow MB, Siddiqui F, Nsa W, Bratzler DW: **Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours?** *Chest* 2006, **130**:16-21.
27. Proulx N, Frechette D, Toye B, Chan J, Kravcik S: **Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis.** *QJM* 2005, **98**:291-298.
28. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: **Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.** *Chest* 2002, **122**:262-268.
29. Mathevon T, Souweine B, Traore O, Aublet B, Caillaud D: **ICU-acquired nosocomial infection: Impact of delay of adequate antibiotic treatment.** *Scand J Infect Dis* 2002, **34**:831-835.
30. Miner JR, Heegaard W, Mapes A, Biros M: **Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center.** *J Emerg Med* 2001, **21**:387-392.
31. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW: **Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.** *Clin Infect Dis* 2003, **37**:745-751.

32. Lodise TP, McKinnon PS, Swiderski L, Ryback MJ: **Outcomes analysis of delayed antibiotic treatment for hospital-acquired *Staphylococcus aureus* bacteremia.** *Clin Infect Dis* 2003, **36**: 1418-1423.
33. Larche J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G, Darmon M, Le Gall JR, Schlemmer B: **Improved survival of critically ill cancer patients with septic shock.** *Intensive Care Med* 2003, **29**:1688-1695.
34. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, *et al.*: **Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.** *Crit Care Med* 2006, **34**:1589-1596.
35. Bochud PY, Bonten M, Marchetti O, Calandra T: **Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review.** *Crit Care Med* 2004, **32**: S495-S512.
36. Girard TD, Opal SM, Ely EW: **Insights into severe sepsis in older patients: from epidemiology to evidence-based management.** *Clin Infect Dis* 2005, **40**:719-727.
37. Groeneveld ABJ, Thijs LG: **Diagnosis: from clinical signs to haemodynamic evaluation.** In *Septic Shock*. Edited by Dhainaut JF, Thijs LG, Park G. London, UK: WB Saunders; 2000:355-386.
38. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB: **The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults.** *Clin Infect Dis* 1997, **24**: 584-602.
39. Mortensen EM, Restrepo MI, Anzueto A, Pugh JA: **Antibiotic therapy and 48-hour mortality for patients with pneumonia.** *Am J Med* 2006, **119**:859-864.
40. Butler JC, Bosshardt SC, Phelan M, Moroney SM, Tondella ML, Farley MM, Schuchat A, Fields BS: **Classical and latent class analysis evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of pneumococcal pneumonia in adults.** *J Infect Dis* 2003, **187**:1416-1423.
41. Kistler A, Avila PC, Rouskin S, Wang D, Ward T, Yagi S, Schnurr D, Ganem D, DeRisi JL, Boushey HA: **Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity.** *J Infect Dis* 2007, **196**:817-825.
42. Vincent JL, Gerlach H: **Fluid resuscitation in severe sepsis and septic shock: an evidence-based review.** *Crit Care Med* 2004, **32**:S451-S454.
43. Cochrane Injuries Group Albumin Reviewers: **Human albumin administration in critically ill patients: systematic review of randomised controlled trials.** *BMJ* 1998, **31**:235-240.
44. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators: **A comparison of albumin and saline for fluid resuscitation in the intensive care unit.** *N Engl J Med* 2004, **350**:2247-2256.
45. Guidet B, Mosqueda GJ, Priol G, Aegerter P: **The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock.** *J Crit Care* 2007, **22**:197-203.
46. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: **A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.** *N Engl J Med* 1999, **340**:409-417.
47. Silliman CC, Ambruso DR, Boshkov LK: **Transfusion-related acute lung injury.** *Blood* 2005, **105**:2266-2273.
48. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group: **Early goal directed therapy in the treatment of severe sepsis and septic shock.** *N Engl J Med* 2001, **345**: 1368-1377.
49. Alderson P, Schierhout G, Roberts I, Bunn F: **Colloids versus crystalloids for fluid resuscitation in critically ill patients.** *Cochrane Database Syst Rev* 2004, **4**:CD000567.
50. Schierhout G, Roberts I: **Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials.** *BMJ* 1998, **316**:961-964.
51. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L: **Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study.** *Lancet* 2001, **357**:911-916.
52. Reinhart K, Bloos F, Engel C, on behalf the German Competence Network Sepsis: **Hydroxyethyl starch and Ringer's lactate for fluid resuscitation in patients with severe sepsis: results from the VISEP study [abstract 0818].** *Intens Care Med* 2006, **S1**: 213.
53. Zander R, Boldt J, Engelmann L, Mertzluft F, Sirtl C, Stuttmann R: **The design of the VISEP trial. Critical appraisal [in German].** *Anaesthesist* 2007, **56**:71-77.
54. Beal RB, Hollenberg SM, Vincent JL, Parrillo JE: **Vasopressor and inotropic support in septic shock: an evidence based review.** *Crit Care Med* 2004, **32**(suppl):S455-S465.
55. Hannemann L, Reinhart K, Grenzer O, Meier-Hellmann A, Bredle DL: **Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock.** *Crit Care Med* 1995, **23**:1962-1970.
56. Jakob SM, Ruokonen E, Takala J: **Effects of dopamine on systemic and regional blood flow and metabolism in septic and cardiac surgery patients.** *Shock* 2002, **18**:8-13.
57. Day NP, Phu NH, Bethell DP, Mai NT, Chau TT, Hien TT, White NJ: **The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection.** *Lancet* 1996, **348**:219-223.
58. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, Williams MD: **Early changes in organ function predict eventual survival in severe sepsis.** *Crit Care Med* 2005, **33**:2194-2201.
59. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, Troche G, Ricard JD, Nitenberg G, Papazian L, *et al.*; CATS Study Group: **Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial.** *Lancet* 2007, **370**:676-684.
60. Delmas A, Leone M, Rousseau S, Albanese J, Martin C: **Vasopressin and terlipressin in septic shock patients.** *Crit Care* 2005, **9**:212-222.
61. Barrett LK, Singer M, Clapp LH: **Vasopressin: mechanisms of action on the vasculature in health and in septic shock.** *Crit Care Med* 2007, **35**:33-40.
62. Sebat F, Johnson D, Musthafa AA, Watnik M, Moore S, Henry K, Saari M: **A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients.** *Chest* 2005, **127**:1729-1743.
63. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine: **Practice parameters for hemodynamic support of sepsis in adult patients in sepsis.** *Crit Care Med* 1999, **27**:639-660.
64. Nguyen HB, Corbett SW, Clark RT, Cho T, Wittlake WA: **Improving the uniformity of care with a sepsis bundle in the emergency department.** *Ann Emerg Med* 2005, **46**:S83.
65. Gaieski D, McCoy J, Zeserson E, Chase M, Goyal M: **Mortality benefit after implementation of early goal directed therapy protocol for the treatment of severe sepsis and septic shock.** *Ann Emerg Med* 2005, **46**:S4.
66. Verceles A, Schwarcz RM, Birnbaum P, Mannam P, Patrick H: **S.E.P.S.I.S: sepsis education plus successful implementation and sustainability in the absence of a rapid response team [abstract].** *Chest* 2005, **128**:S181-S182.
67. Gao F, Melody T, Daniels DF, Giles S, Fox S: **The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study.** *Crit Care* 2005, **9**:R764-R770.
68. Kortgen A, Niederprum P, Bauer M: **Implementation of an evidence-based 'standard operating procedure' and outcome in septic shock.** *Crit Care Med* 2006, **34**:943-949.
69. Armstrong R, Salfen SJ: **Results of implementing a rapid response team approach in treatment of shock in a community hospital [abstract].** In *Proceedings of the 43rd Annual Meeting of the Infectious Diseases Society of America*; 6-9 October 2005; San Francisco, California. Arlington, Virginia: Infectious Diseases Society of America; 2005:154.
70. Micek ST, Roubinian N, Heuring T, Bode M, Williams J, Harrison C, Murphy T, Prentice D, Ruoff BE, Kollef MH: **Before-after study of a standardized hospital order set for the management of septic shock.** *Crit Care Med* 2006, **34**:2707-2713.
71. Rogove H, Pyle K: **Collaboration for instituting the surviving sepsis campaign in a community hospital [abstract].** *Crit Care Med* 2005, **33**(suppl):110S.
72. Stenstrom R, Hollohan K, Nebre R, MacRedmond R, Grafstein E,

- Dodek P, Innes G, Hunte G, Harris D, Westman J, *et al.*: **Impact of a sepsis protocol for the management of patients with severe sepsis and septic shock in the emergency department [abstract].** *Can J Emerg Med* 2006, **8**:S16.
73. Otero RM, Nguyen HB, Huang DT, Gaiieski DF, Goyal M, Gunner-son KJ, Trzeciak S, Sherwin R, Holthaus CV, Osborn T, *et al.*: **Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings.** *Chest* 2006, **130**:1579-1595.
  74. Yu DT, Black E, Sands KE, Schwartz JS, Hibberd PL, Graman PS, Lanken PN, Kahn KL, Snydman DR, Parsonnet J, *et al.*; Academic Medical Center Consortium Sepsis Project Working Group: **Severe sepsis: variation in resource and therapeutic modality use among academic centers.** *Crit Care* 2003, **7**:R24-R34.
  75. Angus DC, Shorr AF, White A, Dremsizov TT, Schmitz RJ, Kelley MA; Committee on Manpower for Pulmonary and Critical Care Societies (COMPACCS): **Critical care delivery in the United States: distribution of services and compliance with Leapfrog recommendations.** *Crit Care Med* 2006, **34**:1016-1024.
  76. McCaig LF, Burt CW: **National Hospital Ambulatory Medical Care Survey: 2001 emergency department summary.** *Adv Data* 2003, **335**:1-29.
  77. Trzeciak S, Rivers EP: **Emergency department overcrowding in the United States: an emerging threat to patient safety and public health.** *Emerg Med J* 2003, **20**:402-405.
  78. Kellermann AL: **Crisis in the emergency department.** *N Engl J Med* 2006, **355**:1300-1303.
  79. De Miguel-Yanes JM, Andueza-Lillo JA, Gonzalez-Ramallo VJ, Pastor L, Munoz J: **Failure to implement evidence-based clinical guidelines for sepsis at the ED.** *Am J Emerg Med* 2006, **24**: 553-559.
  80. Levy MM, Pronovost PJ, Dellinger RP, Townsend S, Resar RK, Clemmer TP, Ramsay G: **Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome.** *Crit Care Med* 2004, **32**:S595-S597.
  81. Trzeciak S, Dellinger RP, Abate NL, Cowan RM, Stauss M, Kilgan-non JH, Zanotti S, Parrillo JE: **Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency depart-ment.** *Chest* 2006, **129**:225-232.
  82. Beale R: **Success with the sepsis bundles: going for gold.** In *Proceedings of the 19th Annual Congress of the European Society of Intensive Care Medicine; 24-27 September 2006; Barcelona, Spain.* Brussels, Belgium: European Society of Inten-sive Care Medicine; 2006.
  83. Dhainaut JF, Schlemmer B, Monsallier JF, Huyghebaert MF, Brunet F, Villemant D, Carli A: **Oxygen consumption during septic shock. Effects of inotropic drugs.** *Arch Int Physiol Biochim* 1984, **92**:S57-S64.
  84. Michard F, Teboul JL: **Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence.** *Chest* 2002, **121**: 2000-2008.
  85. Rivers EP, Kruse JA, Jacobsen G, Shah K, Loomba M, Otero R, Childs EW. **The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock.** *Crit Care Med* 2007, **35**:2016-2024.
  86. Sevransky JE, Nour S, Susla GM, Needham DM, Hollenberg S, Pronovost P: **Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature.** *Crit Care* 2007, **11**:R67.
  87. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI: **Treatment of gram-negative bacteremia and shock with human antiserum to a mutant *Escherichia coli*.** *N Engl J Med* 1982, **307**:1225-1230.
  88. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA; IL-1RA Sepsis Syndrome Study Group: **Initial evaluation of human recombi-nant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-con-trolled multicenter trial.** *Crit Care Med* 1994, **22**:12-21.
  89. Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, With-ington S, *et al.*: **Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.** *Crit Care Med* 2001, **29**:765-769.
  90. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: **Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.** *N Engl J Med* 1996, **334**:1697-1702.
  91. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, *et al.*; OPTIMIST Trial Study Group: **Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a random-ized controlled trial.** *JAMA* 2003, **290**:238-247.
  92. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, *et al.*: **Effect of treatment with low doses of hydrocortisone and flu-drocortisone on mortality in patients with septic shock.** *JAMA* 2002, **288**:862-871.
  93. Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, Briegel J, Keh D, Singer M, Moreno R, *et al.*; Cor-ticus Study Group: **Adrenal function in sepsis: the retrospec-tive Corticus cohort study.** *Crit Care Med* 2007, **35**:1012-1018.
  94. Jackson WL Jr: **Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal.** *Chest* 2005, **127**:1031-1038.
  95. Ray DC, McKeown DW: **Effect of induction agent on vasopres-sor and steroid use, and outcome in patients with septic shock.** *Crit Care* 2007, **11**:R56.
  96. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, *et al.*; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: **Efficacy and safety of recombinant human activated protein C for severe sepsis.** *N Engl J Med* 2001, **344**:699-709.
  97. Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JM: **New insights into the protein C pathway: potential implications for the biological activities of drotreco-gin alfa (activated).** *Crit Care* 2005, **9**:S38-S45.
  98. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF: **Effects of drotreco-gin alfa (activated) in human endotoxemia.** *Shock* 2004, **21**:222-229.
  99. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G III, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: **Effects of drotreco-gin alfa (activated) on organ dysfunction in the PROWESS trial.** *Crit Care Med* 2003, **31**: 834-840.
  100. The Acute Respiratory Distress Syndrome Network: **Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory dis-tress syndrome.** *N Engl J Med* 2000, **342**:1301-1308.
  101. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, *et al.*: **Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome.** *N Engl J Med* 1998, **338**:347-354.
  102. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyn-inckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouil-lon R: **Intensive insulin therapy in the critically ill patients.** *N Engl J Med* 2001, **345**:1359-1367.
  103. van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R: **Intensive insulin therapy in the medical ICU.** *N Engl J Med* 2006, **354**:449-461.
  104. Malhotra A: **Intensive insulin in intensive care.** *N Engl J Med* 2006, **354**:516-518.